Uniqure N.V. - (QURE) closed at $21.88 on November 16, 2026, down 8.1% from the previous close, on volume of 951,790 shares (30-day average 1,983,523).
Data as of November 16, 2026.
16-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 4, 2026 | Call Butterfly | 21-Jan-2845 : 50[2x] : 55 C | 1,580 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 13, 2026. See the largest for 5, 30, 60 and 90 days
Analysts Offer Insights on Healthcare Companies: Faeth Therapeutics (FTH) and uniQure (QURE)
TipRanks (Mon, 16-Nov 8:50 AM ET)
uniQure Earnings Call Signals Momentum for AMT-130
TipRanks (Sat, 14-Nov 10:26 PM ET)
uniQure Announces Third Quarter 2026 Financial Results and Provides Company Update
Globe Newswire (Wed, 4-Nov 7:05 AM ET)
uniQure’s Huntington’s gene therapy BLA wins FDA Priority Review, with a May 1, 2027 PDUFA date
Market Chameleon (Mon, 2-Nov 2:31 AM ET)
Globe Newswire (Mon, 2-Nov 7:05 AM ET)
uniQure Sets Nov. 4 Q3 2026 Results Call, With Webcast Replay Archived for 90 Days
Market Chameleon (Wed, 28-Oct 5:41 AM ET)
uniQure to Announce Third Quarter 2026 Financial Results
Globe Newswire (Wed, 28-Oct 7:05 AM ET)
Newsfile (Tue, 13-Oct 7:12 PM ET)
Business Wire (Tue, 6-Oct 6:00 PM ET)
Globe Newswire (Wed, 30-Sep 6:43 PM ET)
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.
Uniqure N.V. - trades on the NASDAQ stock market under the symbol QURE.
As of November 16, 2026, QURE stock price declined to $21.88 with 951,790 million shares trading.
QURE has a beta of 2.70, meaning it tends to be more sensitive to market movements. QURE has a correlation of 0.09 to the broad based SPY ETF.
QURE has a market cap of $1.53 billion. This is considered a Small Cap stock.
Last quarter Uniqure N.V. - reported $5 million in Revenue and -$.88 earnings per share. This fell short of revenue expectation by $-573,200 and missed earnings estimates by -$.06.
In the last 3 years, QURE traded as high as $71.50 and as low as $3.73.
The top ETF exchange traded funds that QURE belongs to (by Net Assets): XBI, VXF, IBB, JGRO, SCHA.
QURE has underperformed the market in the last year with a price return of -27.9% while the SPY ETF gained +11.2%. QURE has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -53.5% and -11.9%, respectively, while the SPY returned -4.6% and -2.1%, respectively.
QURE support price is $22.48 and resistance is $25.14 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that QURE shares will trade within this expected range on the day.